---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-350596"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2026-08-14T12:30:12+00:00"
generated_at: "2026-08-14T12:35:45.572581+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Climb Bio partner Mabworks doses first IgA nephropathy patient in Phase 2 China trial

## Summary
- Beijing Mabworks Biotech announced first patient dosed in Phase 2 trial for immunoglobulin A nephropathy in China.
- Trial is conducted in collaboration with Climb Bio, Inc.; announcement made August 13, 2026.
- Climb Bio disclosed the milestone via Form 8-K on August 14, 2026; no financial terms disclosed.

## SEC filing metadata
- accession: 0001193125-26-350596
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2026-08-14T12:30:12+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000119312526350596/0001193125-26-350596-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000119312526350596/d328636d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-350596
- JSON: https://secwatch.observer/filing/0001193125-26-350596.json
- Plain text: https://secwatch.observer/filing/0001193125-26-350596.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.